Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38238314)

  • 1. The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway.
    Tang M; Yin S; Zeng H; Huang A; Huang Y; Hu Z; Shah AR; Zhang S; Li H; Chen G
    Cell Death Dis; 2024 Jan; 15(1):69. PubMed ID: 38238314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response.
    Li HD; Lu C; Zhang H; Hu Q; Zhang J; Cuevas IC; Sahoo SS; Aguilar M; Maurais EG; Zhang S; Wang X; Akbay EA; Li GM; Li B; Koduru P; Ly P; Fu YX; Castrillon DH
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32699191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
    He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
    Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
    Fang H; Barbour JA; Poulos RC; Katainen R; Aaltonen LA; Wong JWH
    PLoS Genet; 2020 Feb; 16(2):e1008572. PubMed ID: 32012149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Treatment for
    Van Gool IC; Rayner E; Osse EM; Nout RA; Creutzberg CL; Tomlinson IPM; Church DN; Smit VTHBM; de Wind N; Bosse T; Drost M
    Clin Cancer Res; 2018 Jul; 24(13):3197-3203. PubMed ID: 29559562
    [No Abstract]   [Full Text] [Related]  

  • 6. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction.
    Li Y; Bian Y; Wang K; Wan XP
    BMC Med Genet; 2019 Dec; 20(1):202. PubMed ID: 31864301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
    Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
    J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
    Bellone S; Bignotti E; Lonardi S; Ferrari F; Centritto F; Masserdotti A; Pettinella F; Black J; Menderes G; Altwerger G; Hui P; Lopez S; de Haydu C; Bonazzoli E; Predolini F; Zammataro L; Cocco E; Ferrari F; Ravaggi A; Romani C; Facchetti F; Sartori E; Odicino FE; Silasi DA; Litkouhi B; Ratner E; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2017 Jan; 144(1):146-152. PubMed ID: 27894751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis.
    McAlpine JN; Chiu DS; Nout RA; Church DN; Schmidt P; Lam S; Leung S; Bellone S; Wong A; Brucker SY; Lee CH; Clarke BA; Huntsman DG; Bernardini MQ; Ngeow J; Santin AD; Goodfellow P; Levine DA; Köbel M; Kommoss S; Bosse T; Gilks CB; Talhouk A
    Cancer; 2021 Jul; 127(14):2409-2422. PubMed ID: 33793971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
    van Gool IC; Eggink FA; Freeman-Mills L; Stelloo E; Marchi E; de Bruyn M; Palles C; Nout RA; de Kroon CD; Osse EM; Klenerman P; Creutzberg CL; Tomlinson IP; Smit VT; Nijman HW; Bosse T; Church DN
    Clin Cancer Res; 2015 Jul; 21(14):3347-3355. PubMed ID: 25878334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
    Church DN; Briggs SE; Palles C; Domingo E; Kearsey SJ; Grimes JM; Gorman M; Martin L; Howarth KM; Hodgson SV; ; Kaur K; Taylor J; Tomlinson IP
    Hum Mol Genet; 2013 Jul; 22(14):2820-8. PubMed ID: 23528559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the basis of heterogeneity of cancer aggressiveness among the mutated POLE variants.
    Selves J; de Castro E Gloria H; Brunac AC; Saffi J; Guimbaud R; Brousset P; Hoffmann JS
    Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37891003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of a droplet digital PCR assay for detecting
    Kim G; Lee SK; Suh DH; Kim K; No JH; Kim YB; Kim H
    J Gynecol Oncol; 2022 Mar; 33(2):e15. PubMed ID: 34910396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
    Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
    Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the cancer-associated DNA polymerase ε P286R in fission yeast leads to translesion synthesis polymerase dependent hypermutation and defective DNA replication.
    Soriano I; Vazquez E; De Leon N; Bertrand S; Heitzer E; Toumazou S; Bo Z; Palles C; Pai CC; Humphrey TC; Tomlinson I; Cotterill S; Kearsey SE
    PLoS Genet; 2021 Jul; 17(7):e1009526. PubMed ID: 34228709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
    Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
    PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
    Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
    PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
    Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
    BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.
    Bellone S; Centritto F; Black J; Schwab C; English D; Cocco E; Lopez S; Bonazzoli E; Predolini F; Ferrari F; Silasi DA; Ratner E; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2015 Jul; 138(1):11-7. PubMed ID: 25931171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
    Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
    Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.